A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).

A post on inventcures.github.io, published 30 September 2026, has not been cited by any blog yet (corpus.blog, measured 15 October 2026).

A record is what was published and who pointed at it. The text of the post is not shown here: read it at the source, or at its Wayback capture.